AEterna

AEterna is not alone in pursuing anti-angiogenesis.

A Canadian Technology Success Story Cancer Therapy: From Concept to Commonplace 2000

After nearly a decade of hard work, and the support of both capital markets and governmental agencies, AEterna is now very well positioned.

A Canadian Technology Success Story Cancer Therapy: From Concept to Commonplace 2000

AEterna is a Quebec-based biopharmaceutical company with a single guiding mission: to become an international biotech focused on cancer.

A Canadian Technology Success Story Cancer Therapy: From Concept to Commonplace 2000

Biotech research in cancer therapy falls into several categories including antibodies, vaccines, gene therapy, and anti-angiogenesis -- the area that AEterna is particularly excited about.

A Canadian Technology Success Story Cancer Therapy: From Concept to Commonplace 2000

AEterna is promoting this approach to cancer therapy using a substance found in shark cartilage with the goal of finding a treatment for the disease.

A Canadian Technology Success Story Cancer Therapy: From Concept to Commonplace 2000

As I mentioned, our company, AEterna, is based in Quebec City.

A Canadian Technology Success Story Cancer Therapy: From Concept to Commonplace 2000

I am proud to say that AEterna is leading the field.

A Canadian Technology Success Story Cancer Therapy: From Concept to Commonplace 2000

Keryx gained 61 cents, or 22%, to 3.35, while AEterna Zentaris climbed 15 cents, or 19%, to 95 cents.

Swift Energy and Beazer Move Higher; Arena Up Too Kristina Peterson 2010

Keryx gained 61 cents, or 22%, to 3.35, while AEterna Zentaris climbed 15 cents, or 19%, to 95 cents.

Swift Energy and Beazer Move Higher; Arena Up Too Kristina Peterson 2010

Keryx gained 61 cents, or 22%, to 3.35, while AEterna Zentaris climbed 15 cents, or 19%, to 95 cents.

Swift Energy and Beazer Move Higher; Arena Up Too Kristina Peterson 2010